Phio Pharmaceuticals Files 8-K
Ticker: PHIO · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, sec-filing
TL;DR
Phio Pharma filed an 8-K on Nov 3rd, standard corporate update.
AI Summary
Phio Pharmaceuticals Corp. filed an 8-K on November 3, 2025, reporting on other events and financial statements. The company, formerly known as RXi Pharmaceuticals Corp., is incorporated in Delaware and headquartered in King of Prussia, PA. This filing does not appear to contain specific transactional details or financial figures beyond the reporting date.
Why It Matters
This 8-K filing indicates a routine update from Phio Pharmaceuticals Corp. to the SEC, signaling ongoing corporate activity without immediate material news.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for 'Other Events' and 'Financial Statements and Exhibits' without disclosing specific material events or financial changes.
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- RXi Pharmaceuticals Corp (company) — Former company name
- November 3, 2025 (date) — Date of report
- King of Prussia, PA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Phio Pharmaceuticals Corp.?
This 8-K filing is for 'Other Events' and 'Financial Statements and Exhibits', indicating a routine corporate update.
When was this 8-K report filed?
The report was filed on November 3, 2025.
What was Phio Pharmaceuticals Corp. formerly known as?
Phio Pharmaceuticals Corp. was formerly known as RXi Pharmaceuticals Corp.
Where are Phio Pharmaceuticals Corp.'s principal executive offices located?
The principal executive offices are located at 411 Swedeland Road, Suite 23-1080, King of Prussia, PA 19406.
Does this filing disclose any specific new material events or financial transactions?
Based on the provided text, this filing appears to be a general update and does not disclose specific new material events or financial transactions.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-11-03 08:01:06
Key Financial Figures
- $0.0001 — h registered: Common Stock , par value $0.0001 per share PHIO The Nasdaq Capital M
Filing Documents
- phio20251023_8k.htm (8-K) — 24KB
- ex_875368.htm (EX-99.1) — 12KB
- logo.jpg (GRAPHIC) — 7KB
- 0001437749-25-032662.txt ( ) — 181KB
- phio-20251103.xsd (EX-101.SCH) — 3KB
- phio-20251103_def.xml (EX-101.DEF) — 12KB
- phio-20251103_lab.xml (EX-101.LAB) — 15KB
- phio-20251103_pre.xml (EX-101.PRE) — 12KB
- phio20251023_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On November 3, 2025, Phio Pharmaceuticals Corp. ("Phio") issued a press release announcing (i) 100% tumor clearance (Complete Response) in one patient, greater than 90% (Near Complete Response) in second patient and greater than 50% (Partial Response) in third patient at Day 36 with cutaneous squamous cell carcinoma and (ii) that the Safety Monitoring Committee has issued a favorable review of safety data at the maximum dose of INTASYL PH-762. These patients completed treatment in the fifth and final dose cohort of Phio's ongoing Phase 1b dose escalation clinical trial (NCT 06014086). The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on November 3, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: November 3, 2025 By: /s/ Robert J. Bitterman Robert J. Bitterman President & Chief Executive Officer 3